Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells

Haematologica

Volumn 90, Issue 12, 2005, Pages 1607-1616

  Yan, Hua ^a   Peng, Zhen Gang ^b   Wu, Ying Li ^a   Jiang, Yi ^a   Yu, Yun ^a   Huang, Ying ^a   Zhu, Yuan Shan ^c   Zhao, Qian ^b   Chen, Guo Qiang ^a,b,d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NONE   (China)

Author keywords

Arsenic trioxide; Differentiation; Hypoxia; Hypoxia inducible factor 1

Indexed keywords

ANTIGEN; ARSENIC TRIOXIDE; BIOLOGICAL MARKER; COBALT CHLORIDE; DEFEROXAMINE; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN; PROTEIN RARALPHA; UNCLASSIFIED DRUG; ZINC ION;

ARTICLE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER INHIBITION; CELL DIFFERENTIATION; CELL STRAIN U937; CELL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FUSION GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LEUKEMIA CELL; LOW DRUG DOSE; MOLECULAR CLONING; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; ARSENICALS; BONE MARROW; CELL DIFFERENTIATION; CELL DIVISION; CELL HYPOXIA; CELL LINE, TUMOR; COBALT; DEFEROXAMINE; DRUG SYNERGISM; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; OXIDES; OXYGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRETINOIN; U937 CELLS;

EID: 29144471201     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Awisati G, Lo Coco F, Mandelli F. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. Semin Hematol 2001;38:4-12.
2. Puccetti E, Ruthardt M. Acute promyelocytic leukemia: PML/RARα and the leukemic stem cell. Leukemia 2004; 18: 1169-75.
3. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-84.
4. Diverio D, Lo Coco F, D'Adamo F, Biondi A, Fagioli M, Grignani F, et al. Identification of DNA rearrangements at the retinoic acid receptor-α (RAR-α) locus in all patients with acute promyelocytic leukemia (APL) and mapping of APL breakpoints within the RAK-a second intron. Italian Cooperative Study Group "GIMEMA". Blood 1992; 79: 3331-6.
5. Brown D. Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, et al. A PML-RARa transgene initiates murine acute promyelocytic leukemia. Proc Nad Acad Sci USA 1997;94:2551-6.
6. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences. Blood 1997;89:376-87.
7. Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A, et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 2002;100:2989-95.
8. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-72.
9. Lo Coco F, Zelent A, Kimchi A, Carduci M, Gore SD, Waxman S. Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond. Cancer Res 2002;62:5618-21.
10. Tallmann MS. Curative therapeutic approaches to APL. Ann Hematol 2004; 83:S81-2.
11. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-60.
12. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341-8.
13. Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003;97:2218-24.
14. Carmosino I, Latagliata R, Awisati G, Breccia M, Finolezzi E, Lo Coco F, et al. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 2004; 89:615-7.
15. Chen GQ, Cai X. Clinical and experimental studies on arsenicals in treatment of hematopoietic malignancies. In: Niho Y, ed: Molecular Target for Hematological Malignancies and Cancer. Kyushu University Press; 2000. p. 85-93.
16. Cohen MH, Hirschfeld S, Flamm Honig S, Ibrahim A, Johnson JR, et al. Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 2001;6:4-11.
17. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101:5328-35.
18. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-53.
19. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189:1043-52.
20. Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, et al. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000; 14:431-8.
21. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia: ATO induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PMLRARα/PML proteins. Blood 1996; 88: 1052-61.
22. Chen GQ, Wang Q, Yan H, Chen Z. Arsenic trioxide and leukemia: from bedside to bench. In Zhang LX and Demain AL Eds, Natural Products: Drug Discovery and Therapeutic Medicine. New Jersy: Humana Press Inc. 2005. 245-66.
23. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000;14:262-70.
24. Sun Y, Kim SH, Zhou DC, Ding W, Paietta E, Guidez F, et al. Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide. Leukemia 2004; 18: 1258-69.
25. Huang Y, Du KM, Xue ZH, Yan H, Li D, Liu W, et al. Cobalt chloride and low oxygen tension trigger differentiation or acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1α. Leukemia 2003; 17: 2065-73.
26. Jiang Y, Shen WJ, Xue ZH, Yan H, Peng ZG, Tong JH, et al. Desferrioxamine induces leukemic cell differentiation by hypoxia inducible factor-1α and CCAAT/enhancer-binding protein-α-dependent mechanisms. Leukemia 2005;19:1239-47.
27. Xue ZH, Jiang Y, Yu Y, Wang LS, Chen GQ, Zhao Q. Metavanadate suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia inducible factor-1α protein. Biochem Biophys Res Commun 2005; 332:1140.
28. Aldinucci D, Gelmetti V, Fagioli M, Alcalay M, Seeler J, Grignani F, et al. Effects on differentiation by the promyelocytic leukemia PML/RARα protein depend on the fusion of the PML protein dimerization and RARa DNA binding domains. EMBO J 1996; 15: 4949-57.
29. Lee P, Mohammed N, Marshall L, Abevsinghe RD, Hider RC, Porter JB, et al. Intravenous infusion pharmaco-kinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos 1993;21:640-4.
30. Zhu J, Shi XG, Chu HY, Tong JH, Wang ZY, Naoe T, et al. Effect of retinoic acid isomers on proliferation, differentiation and PML relocalization in the APL cell line NB4. Leukemia 1995;9:302-9.
31. Zhao KW, Li X, Zhao Q, Huang Y, Peng ZG, Shen WZ, et al. Protein kinase Cd mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood 2004;104:3731-8.
32. Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nature Genetics 2004;36:257-63.
33. Zhu J, Koken MH, Quignon A, Chelbi-Alix MK, Degos L, Wang ZY, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94:3978-83.
34. Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998;17:61-70.
35. Hayakawa F, Privalsky ML. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 2004;5:307-9.
36. Jensen PO, Mortensen BT, Hodgkiss RJ, Iversen PO, Christensen IJ, Helledie N, et al. Increased cellular hypoxia and reduced proliferation of both normal and Ieukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif 2000;33:381-95.
37. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
38. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1a. J Biol Chem 2002;277:40112-7.
39. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, et al. The acute promyelocytic leukemia specific PML/RARa protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74:423-31.
40. Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, et al. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 1999;19:5170-8.
41. Puccetti E, Beissert T, Culler S, Li JE, Hoelzer D, Ottmann OG, et al. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. Oncogene 2003;22:6900-8.
42. Mayerhof er M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, througn a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002;100:3767-75.